The earnings call presented a strong performance for Zoetis, with significant growth in revenue and key product portfolios, particularly in companion animal products. Despite some challenges in the China market and the impact of strategic divestitures, the company remains confident in its growth trajectory and market leadership.

Company Guidance

During the Zoetis Q3 2024 earnings call, the company provided comprehensive guidance, highlighting key financial metrics. Revenue grew by 14% operationally, with adjusted net income increasing by 15% operationally. The U.S. market saw a 15% growth, while international revenue grew 13% operationally. The companion animal portfolio expanded by 15% operationally, and livestock grew by 11%. Specific product successes included 97% operational revenue growth globally for the osteoarthritis pain franchise, Librela and Valencia. Simparica Trio, the top vet-prescribed parasiticide, saw a 27% operational growth. The company raised its full-year revenue guidance to $9.2 - $9.3 billion, reflecting 10% - 11% operational growth, with adjusted net income projected between $2.67 billion and $2.695 billion, indicating an operational growth of 13.5% - 14.5%. Adjusted diluted EPS is expected to range from $5.86 to $5.92. Zoetis emphasized a strategic focus on innovation and market expansion, poised for continued growth into 2025.

Impressive Revenue and Income Growth

Revenue grew 14% operationally, and adjusted net income increased by 15% operationally.

Record Performance in Companion Animal Portfolio

Innovative companion animal portfolio grew 15% operationally, with strong demand for Librela and Simparica Trio.

Librela's Transformative Impact

Librela achieved 97% operational revenue growth globally, becoming the fourth largest product in U.S. pet care in just 11 months.

Strong Growth in Simparica Franchise

Simparica franchise grew 27% operationally with Simparica Trio becoming the #1 vet prescribed parasiticide.

Dermatology Franchise Success

Dermatology franchise demonstrated 16% operational growth driven by products like Apoquel and Cytopoint.

Strategic Divestiture in Livestock

Sale of medicated feed additives to Phibro Animal Health to focus on high-growth potential areas.

---

Zoetis (ZTS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ZTS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 02, 2018	2018 (Q2)	- / 0.77	0.53	45.28% (+0.24)	―	―
Nov 01, 2018	2018 (Q3)	- / 0.83	0.65	27.69% (+0.18)	―	―
Feb 14, 2019	2018 (Q4)	- / 0.79	0.69	14.49% (+0.10)	―	―
May 02, 2019	2019 (Q1)	- / 0.88	0.75	17.33% (+0.13)	―	―
Aug 06, 2019	2019 (Q2)	- / 0.90	0.77	16.88% (+0.13)	―	―
Nov 07, 2019	2019 (Q3)	- / 0.94	0.83	13.25% (+0.11)	―	―
Feb 13, 2020	2019 (Q4)	- / 0.92	0.79	16.46% (+0.13)	―	―
May 06, 2020	2020 (Q1)	- / 0.95	0.88	7.95% (+0.07)	―	―
Aug 06, 2020	2020 (Q2)	- / 0.89	0.9	-1.11% (-0.01)	―	―
Nov 05, 2020	2020 (Q3)	- / 1.10	0.94	17.02% (+0.16)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

---

ZTS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 04, 2024	$181.95	$175.18	-3.72%
Aug 06, 2024	$174.41	$184.85	+5.99%
May 02, 2024	$157.75	$166.44	+5.51%
Feb 13, 2024	$195.20	$182.10	-6.71%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

---